Unlocking the Potential of Rucaparib: A Case Series on Its Impact in Metastatic Breast Cancer With Mutations

Triple-negative breast cancer poses distinct challenges because it lacks hormone receptors and does not have human epidermal growth factor receptor 2 (HER2) amplification. Mutations in BRCA1/2 genes are associated with homologous recombination deficiency tumors, rendering them susceptible to poly (A...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Curēus (Palo Alto, CA) CA), 2024-05, Vol.16 (5), p.e60963
Hauptverfasser: Mv, Chandrakanth, Agarwala, Vivek, Choudhary, Neha, Sharma, Amit, Roy, Minakshi, Mandal, Kaustav, Basu, Moinak, Sen, Nibedita, Sarkar, Pritam K, Kumar, Subhabrata
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page e60963
container_title Curēus (Palo Alto, CA)
container_volume 16
creator Mv, Chandrakanth
Agarwala, Vivek
Choudhary, Neha
Sharma, Amit
Roy, Minakshi
Mandal, Kaustav
Basu, Moinak
Sen, Nibedita
Sarkar, Pritam K
Kumar, Subhabrata
description Triple-negative breast cancer poses distinct challenges because it lacks hormone receptors and does not have human epidermal growth factor receptor 2 (HER2) amplification. Mutations in BRCA1/2 genes are associated with homologous recombination deficiency tumors, rendering them susceptible to poly (ADP-ribose) polymerase (PARP) inhibitors. Notably, germline BRCA1/2 mutations are linked to distinct clinical features, including an increased risk of triple-negative breast cancer (TNBC) and a younger age of onset. PARP inhibitors such as olaparib and talazoparib have demonstrated efficacy in patients with BRCA mutations, leading to FDA approvals for ovarian and breast cancers. However, there remains limited data on PARP inhibitor response rates in patients with somatic BRCA mutations. This case series demonstrates the use of rucaparib in metastatic breast cancer patients harboring both germline and somatic BRCA1/2 mutations, discussing the advancing landscape of targeted therapies in breast cancer management. In the first case, despite undergoing anthracycline-based chemotherapy followed by hormonal therapy, disease progression ensued. However, transitioning to rucaparib yielded a remarkable complete response lasting over two years, highlighting its efficacy in this clinical setting. Similarly, in the second case, rucaparib demonstrated effectiveness as a maintenance therapy subsequent to achieving a near-complete response to taxane and platinum-based treatment. These findings emphasize the promising role of rucaparib in managing metastatic breast cancer in patients with BRCA1/2 mutations, further contributing to the expanding armamentarium of targeted therapies in breast cancer care.
doi_str_mv 10.7759/cureus.60963
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11193870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3071513327</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-f6fb1616b28f59e9145b07f7de1adb2f2ccf7dbcc00b53fd89155facb9693c793</originalsourceid><addsrcrecordid>eNpdkc1LXDEUxYNUVKy7riXQTRcdvXnxvbx0U-zQjwHFohWXIcncOLFvkjHJK_S_b6ajoq7uvZwfh3s4hLxjcCREK4_tmHDMRx3Ijm-RvYZ1_aRn_cmbZ_suOcj5DgAYiAYE7JBd3st6gNgjw3UYov3twy0tC6Q_Y8FQvB5odPRytHqlkzef6Cmd6oz0CpPHTGOgs5LpbLnStlAf6DkWnYsu3tIvCeta8WAx0RtfFvR8XEsx5Ldk2-kh48HD3CfX377-mv6YnF18n01PzyaWA5SJ65xhHetM07tWomQnrQHhxByZnpvGNdbWw1gLYFru5jVM2zptjewkt0LyffJ547sazRLntkZKelCr5Jc6_VVRe_VSCX6hbuMfxRiTvBdQHT48OKR4P2IuaumzxWHQAeOYFQfBWsZ5Iyr6_hV6F8cUar41xfuu5YJV6uOGsinmnNA9fcNAratUmyrV_yorfvg8wRP8WBz_B_j2nAI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3073865371</pqid></control><display><type>article</type><title>Unlocking the Potential of Rucaparib: A Case Series on Its Impact in Metastatic Breast Cancer With Mutations</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Mv, Chandrakanth ; Agarwala, Vivek ; Choudhary, Neha ; Sharma, Amit ; Roy, Minakshi ; Mandal, Kaustav ; Basu, Moinak ; Sen, Nibedita ; Sarkar, Pritam K ; Kumar, Subhabrata</creator><creatorcontrib>Mv, Chandrakanth ; Agarwala, Vivek ; Choudhary, Neha ; Sharma, Amit ; Roy, Minakshi ; Mandal, Kaustav ; Basu, Moinak ; Sen, Nibedita ; Sarkar, Pritam K ; Kumar, Subhabrata</creatorcontrib><description>Triple-negative breast cancer poses distinct challenges because it lacks hormone receptors and does not have human epidermal growth factor receptor 2 (HER2) amplification. Mutations in BRCA1/2 genes are associated with homologous recombination deficiency tumors, rendering them susceptible to poly (ADP-ribose) polymerase (PARP) inhibitors. Notably, germline BRCA1/2 mutations are linked to distinct clinical features, including an increased risk of triple-negative breast cancer (TNBC) and a younger age of onset. PARP inhibitors such as olaparib and talazoparib have demonstrated efficacy in patients with BRCA mutations, leading to FDA approvals for ovarian and breast cancers. However, there remains limited data on PARP inhibitor response rates in patients with somatic BRCA mutations. This case series demonstrates the use of rucaparib in metastatic breast cancer patients harboring both germline and somatic BRCA1/2 mutations, discussing the advancing landscape of targeted therapies in breast cancer management. In the first case, despite undergoing anthracycline-based chemotherapy followed by hormonal therapy, disease progression ensued. However, transitioning to rucaparib yielded a remarkable complete response lasting over two years, highlighting its efficacy in this clinical setting. Similarly, in the second case, rucaparib demonstrated effectiveness as a maintenance therapy subsequent to achieving a near-complete response to taxane and platinum-based treatment. These findings emphasize the promising role of rucaparib in managing metastatic breast cancer in patients with BRCA1/2 mutations, further contributing to the expanding armamentarium of targeted therapies in breast cancer care.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.60963</identifier><identifier>PMID: 38910707</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Breast cancer ; FDA approval ; Mutation ; Oncology ; Ovarian cancer</subject><ispartof>Curēus (Palo Alto, CA), 2024-05, Vol.16 (5), p.e60963</ispartof><rights>Copyright © 2024, MV et al.</rights><rights>Copyright © 2024, MV et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2024, MV et al. 2024 MV et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-f6fb1616b28f59e9145b07f7de1adb2f2ccf7dbcc00b53fd89155facb9693c793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193870/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11193870/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38910707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mv, Chandrakanth</creatorcontrib><creatorcontrib>Agarwala, Vivek</creatorcontrib><creatorcontrib>Choudhary, Neha</creatorcontrib><creatorcontrib>Sharma, Amit</creatorcontrib><creatorcontrib>Roy, Minakshi</creatorcontrib><creatorcontrib>Mandal, Kaustav</creatorcontrib><creatorcontrib>Basu, Moinak</creatorcontrib><creatorcontrib>Sen, Nibedita</creatorcontrib><creatorcontrib>Sarkar, Pritam K</creatorcontrib><creatorcontrib>Kumar, Subhabrata</creatorcontrib><title>Unlocking the Potential of Rucaparib: A Case Series on Its Impact in Metastatic Breast Cancer With Mutations</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Triple-negative breast cancer poses distinct challenges because it lacks hormone receptors and does not have human epidermal growth factor receptor 2 (HER2) amplification. Mutations in BRCA1/2 genes are associated with homologous recombination deficiency tumors, rendering them susceptible to poly (ADP-ribose) polymerase (PARP) inhibitors. Notably, germline BRCA1/2 mutations are linked to distinct clinical features, including an increased risk of triple-negative breast cancer (TNBC) and a younger age of onset. PARP inhibitors such as olaparib and talazoparib have demonstrated efficacy in patients with BRCA mutations, leading to FDA approvals for ovarian and breast cancers. However, there remains limited data on PARP inhibitor response rates in patients with somatic BRCA mutations. This case series demonstrates the use of rucaparib in metastatic breast cancer patients harboring both germline and somatic BRCA1/2 mutations, discussing the advancing landscape of targeted therapies in breast cancer management. In the first case, despite undergoing anthracycline-based chemotherapy followed by hormonal therapy, disease progression ensued. However, transitioning to rucaparib yielded a remarkable complete response lasting over two years, highlighting its efficacy in this clinical setting. Similarly, in the second case, rucaparib demonstrated effectiveness as a maintenance therapy subsequent to achieving a near-complete response to taxane and platinum-based treatment. These findings emphasize the promising role of rucaparib in managing metastatic breast cancer in patients with BRCA1/2 mutations, further contributing to the expanding armamentarium of targeted therapies in breast cancer care.</description><subject>Breast cancer</subject><subject>FDA approval</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkc1LXDEUxYNUVKy7riXQTRcdvXnxvbx0U-zQjwHFohWXIcncOLFvkjHJK_S_b6ajoq7uvZwfh3s4hLxjcCREK4_tmHDMRx3Ijm-RvYZ1_aRn_cmbZ_suOcj5DgAYiAYE7JBd3st6gNgjw3UYov3twy0tC6Q_Y8FQvB5odPRytHqlkzef6Cmd6oz0CpPHTGOgs5LpbLnStlAf6DkWnYsu3tIvCeta8WAx0RtfFvR8XEsx5Ldk2-kh48HD3CfX377-mv6YnF18n01PzyaWA5SJ65xhHetM07tWomQnrQHhxByZnpvGNdbWw1gLYFru5jVM2zptjewkt0LyffJ547sazRLntkZKelCr5Jc6_VVRe_VSCX6hbuMfxRiTvBdQHT48OKR4P2IuaumzxWHQAeOYFQfBWsZ5Iyr6_hV6F8cUar41xfuu5YJV6uOGsinmnNA9fcNAratUmyrV_yorfvg8wRP8WBz_B_j2nAI</recordid><startdate>20240523</startdate><enddate>20240523</enddate><creator>Mv, Chandrakanth</creator><creator>Agarwala, Vivek</creator><creator>Choudhary, Neha</creator><creator>Sharma, Amit</creator><creator>Roy, Minakshi</creator><creator>Mandal, Kaustav</creator><creator>Basu, Moinak</creator><creator>Sen, Nibedita</creator><creator>Sarkar, Pritam K</creator><creator>Kumar, Subhabrata</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240523</creationdate><title>Unlocking the Potential of Rucaparib: A Case Series on Its Impact in Metastatic Breast Cancer With Mutations</title><author>Mv, Chandrakanth ; Agarwala, Vivek ; Choudhary, Neha ; Sharma, Amit ; Roy, Minakshi ; Mandal, Kaustav ; Basu, Moinak ; Sen, Nibedita ; Sarkar, Pritam K ; Kumar, Subhabrata</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-f6fb1616b28f59e9145b07f7de1adb2f2ccf7dbcc00b53fd89155facb9693c793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Breast cancer</topic><topic>FDA approval</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mv, Chandrakanth</creatorcontrib><creatorcontrib>Agarwala, Vivek</creatorcontrib><creatorcontrib>Choudhary, Neha</creatorcontrib><creatorcontrib>Sharma, Amit</creatorcontrib><creatorcontrib>Roy, Minakshi</creatorcontrib><creatorcontrib>Mandal, Kaustav</creatorcontrib><creatorcontrib>Basu, Moinak</creatorcontrib><creatorcontrib>Sen, Nibedita</creatorcontrib><creatorcontrib>Sarkar, Pritam K</creatorcontrib><creatorcontrib>Kumar, Subhabrata</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mv, Chandrakanth</au><au>Agarwala, Vivek</au><au>Choudhary, Neha</au><au>Sharma, Amit</au><au>Roy, Minakshi</au><au>Mandal, Kaustav</au><au>Basu, Moinak</au><au>Sen, Nibedita</au><au>Sarkar, Pritam K</au><au>Kumar, Subhabrata</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unlocking the Potential of Rucaparib: A Case Series on Its Impact in Metastatic Breast Cancer With Mutations</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2024-05-23</date><risdate>2024</risdate><volume>16</volume><issue>5</issue><spage>e60963</spage><pages>e60963-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Triple-negative breast cancer poses distinct challenges because it lacks hormone receptors and does not have human epidermal growth factor receptor 2 (HER2) amplification. Mutations in BRCA1/2 genes are associated with homologous recombination deficiency tumors, rendering them susceptible to poly (ADP-ribose) polymerase (PARP) inhibitors. Notably, germline BRCA1/2 mutations are linked to distinct clinical features, including an increased risk of triple-negative breast cancer (TNBC) and a younger age of onset. PARP inhibitors such as olaparib and talazoparib have demonstrated efficacy in patients with BRCA mutations, leading to FDA approvals for ovarian and breast cancers. However, there remains limited data on PARP inhibitor response rates in patients with somatic BRCA mutations. This case series demonstrates the use of rucaparib in metastatic breast cancer patients harboring both germline and somatic BRCA1/2 mutations, discussing the advancing landscape of targeted therapies in breast cancer management. In the first case, despite undergoing anthracycline-based chemotherapy followed by hormonal therapy, disease progression ensued. However, transitioning to rucaparib yielded a remarkable complete response lasting over two years, highlighting its efficacy in this clinical setting. Similarly, in the second case, rucaparib demonstrated effectiveness as a maintenance therapy subsequent to achieving a near-complete response to taxane and platinum-based treatment. These findings emphasize the promising role of rucaparib in managing metastatic breast cancer in patients with BRCA1/2 mutations, further contributing to the expanding armamentarium of targeted therapies in breast cancer care.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>38910707</pmid><doi>10.7759/cureus.60963</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2024-05, Vol.16 (5), p.e60963
issn 2168-8184
2168-8184
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11193870
source PubMed Central Open Access; PubMed Central
subjects Breast cancer
FDA approval
Mutation
Oncology
Ovarian cancer
title Unlocking the Potential of Rucaparib: A Case Series on Its Impact in Metastatic Breast Cancer With Mutations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A32%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unlocking%20the%20Potential%20of%20Rucaparib:%20A%20Case%20Series%20on%20Its%20Impact%20in%20Metastatic%20Breast%20Cancer%20With%20Mutations&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Mv,%20Chandrakanth&rft.date=2024-05-23&rft.volume=16&rft.issue=5&rft.spage=e60963&rft.pages=e60963-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.60963&rft_dat=%3Cproquest_pubme%3E3071513327%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3073865371&rft_id=info:pmid/38910707&rfr_iscdi=true